Rejoni announced today the completion of a $25 million Series B financing round. Catalyst Health Ventures led the round, with Ascension Health Ventures, Delos Capital, Sparta Group, Amed Ventures, and Iyengar Capital Partners also participating.
Rejoni is a privately held medical technology company that designs and develops hydrogels to improve women’s health care standards. Rejoni’s first product, the JuveenaTM Hydrogel System (HS), is currently being studied in the United States as part of an IDE pivotal study. The Juveena HS is being developed as a temporary implant to prevent the formation of intrauterine adhesions (IUA) inside the uterine cavity after transcervical gynecological procedures.
The funds raised in this round will be used to complete this historic study as well as to investigate potential therapeutic indications in Women’s Health.
Rejoni, Inc. is a privately held company based in Bedford, MA focused on the development and commercialization of gynecological products using its proprietary biomaterials. The company, founded in June 2020, is the latest by serial entrepreneur Amar Sawhney who also founded Confluent Surgical, Ocular Therapeutix and Augmenix, Inc.
